No Survival Advantage When Chemotherapy Is Given Prior to Transplant in R/R AML
February 14th 2023In the phase 3 ETAL3-ASAP trial, patients with relapsed/refractory acute myeloid leukemia given an allogeneic hematopoietic cell transplant had similar overall survival rates vs those given intense salvage chemotherapy first.
Yu Highlights Possible Sequencing Strategies in mCRPC
January 22nd 2023In a presentation delivered at the 2022 Large Urology Group Practice Association Annual Meeting, Evan Y. Yu, MD, discussed different sequencing strategies that can be utilized for patients with mCRPC and the data that support each approach.
Percentage of Actionable Mutations in Prostate Cancer Underscores Importance of Testing
November 12th 2022During a presentation, Emmanuel S. Antonarakis, MD explained that homologous repair mutations and mismatch mutations in prostate cancer have therapeutic implications in the context of PARP inhibitors and PD-1 inhibitors.
Regorafenib Then Nivolumab Sequence Is Tolerable After First-Line HCC Treatment
October 14th 2022Data presented during the 2022 International Liver Cancer Association Conference showed that less than one-third of patients with hepatocellular carcinoma who received regorafenib followed by nivolumab experienced grade 3 or 4 treatment-related adverse events.
Lenvatinib/Pembrolizumab Appears Safe in Metastasized Anaplastic Thyroid Carcinoma
September 13th 2022Data presented during the 2022 ESMO Congress showed lenvatinib plus pembrolizumab to elicit an objective response rate of 34.3% after 3 months in evaluable patients, meeting the primary end point of the phase 2 ATLEP trial.
First-line Olaparib Triplet Improves Outcomes in mCRPC
September 11th 2022Signs of an overall survival benefit were seen with a regimen of olaparib plus abiraterone acetate and prednisone or prednisolone as a first-line therapy for patients with metastatic castration-resistant prostate cancer, according to updated data from the phase 3 PROpel trial.
Dara-RVd Reduces Risk of Progression or Death in Transplant-Eligible NDMM
August 28th 2022The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.
Carfilzomib Plus Lenalidomide/Dexamethasone After Transplant Extends PFS Over Lenalidomide in MM
August 26th 2022Data presented at the 19th International Myeloma Society Annual Meeting show that carfilzomib plus lenalidomide and dexamethasone after transplant prolongs progression-free survival compared with lenalidomide alone in patients with myeloma.
Ibrutinib/Venetoclax Combination Improves MRD Negativity in Blood, Marrow in CLL
August 25th 2022Data from the planned interim analysis of the FLAIR trial show that venetoclax plus ibrutinib can achieved minimal residual disease negativity in patient with treatment-naïve chronic lymphocytic leukemia.
Pelabresib and Ruxolitinib Combination Proves Durable in Patients With Myelofibrosis
August 21st 2022Results from the MANIFEST study of pelabresib and ruxolitinib in myelfibrosis are positive. The phase MANIFEST-2 study continue to explored the combination in JAK inhibitor–naïve patients with myelofibrosis.
Upfront Avelumab Shows Modest Survival Benefit Over Chemo in Advanced PD-L1+ NSCLC
August 9th 2022Survival outcomes of avelumab in patients with PD-L1-positive non-small cell lung cancer showed numeric improvement compared with chemotherapy, but missed the significance threshold in the JAVELIN Lung 100 study.
PARP Inhibitor Regimen Leads to Promising ORR in ES-SCLC
August 8th 2022The combination of talazoparib and temozolomide elicited an objective response rate of 39.3% in patients with extensive-stage small cell lung cancer who were relapsed or refractory to a frontline platinum-based chemotherapy regimen, according to data from a phase 2 UCLA/TRIO-US L-07 trial.
Nivo/Ipi Induces Promising Response in Advanced tTMB- and bTMB-High Solid Tumors
April 11th 2022Results from the phase 2 CheckMate-848 study show that nivolumab in combination and ipilimumab may be effective for the treatment of advanced or metastatic tumor mutational burden–high solid tumors that were refractory to standard therapies.